Hepatic osteodystrophy and liver cirrhosis.
OBJECTIVE
To investigate the correlation between hepatic osteodystrophy and osteoporosis in patients with liver cirrhosis.


METHODS
Bone mineral density of the patients (n = 55) and that of the control group (n = 30) were measured by dual-energy X-ray absorptiometry. All the women in the study were premenopausal. Deoxypyridinoline, pyridinoline and urinary Ca(2+) were measured as bone destruction markers, while alkaline phosphatase (ALP), osteocalcin and insulin-like growth factor-1 (IGF-1) were measured as bone formation markers. Furthermore, interleukin-1 (IL-1), IL-6, tumor necrosis factor alpha (TNF-alpha), vitamin D3, direct bilirubin, albumin, cortisol and parathyroid hormone (PTH) levels were measured. The independent Student t test and chi(2) test were employed in comparing both groups, and the Pearson correlation test was used to determine associations.


RESULTS
Comparing cirrhosis and control groups, lumbar total T-score (-1.6 + or - 1.2 g/cm(2) vs -0.25 + or - 1.3 g/cm(2), P < 0.001), lumbar total Z-score (-1.2 + or - 1.23 g/cm(2) vs -0.6 + or - 1.3 g/cm(2), P < 0.001), total femur T-score (-0.05 + or - 1 g/cm(2) vs -0.6 + or - 0.9 g/cm(2), P = 0.003) and total femur Z-score (-0.08 + or - 1.5 g/cm(2) vs 0.7 + or - 0.9 g/cm(2), P = 0.003) showed significantly lower values in the cirrhosis group. Blood ALP level (109.2 + or - 57 U/L vs 62.6 + or - 32.5 U/L, P < 0.001), IL-6 level (27.9 + or - 51.6 pg/mL vs 3.3 + or - 3.1 pg/mL, P = 0.01), TNF-alpha level (42.6 + or - 33.2 pg/mL vs 25.3 + or - 12.3 pg/mL, P = 0.007) and direct bilirubin level (0.9 + or - 0.7 mg/dL vs 0.3 + or - 0.2 mg/dL, P < 0.001) were significantly higher in the cirrhosis group. IGF-1 level (47.7 + or - 26.2 ng/mL vs 143.4 + or - 53.2 ng/mL, P < 0.001), osteocalcin level (1.05 + or - 2.5 ng/mL vs 7.0 + or - 13 ng/mL, P = 0.002) and 24 h urinary Ca(2+) (169.6 + or - 227.2 mg/dL vs 287 + or - 168.6 mg/dL, P = 0.003) were significantly lower in the cirrhosis group. Urinary deoxypyridinoline/creatinine (9.4 + or - 9.9 pmol/micromol vs 8.1 + or - 5.3 pmol/micromol, P = 0.51), urinary pyridinoline/creatinine (51.3 + or - 66.6 pmol/micromol vs 29 + or - 25.8 pmol/micromol, P = 0.08), blood IL-1 level (3.4 + or - 8.8 pg/mL vs 1.6 + or - 3.5 pg/mL, P = 0.29), vitamin D3 level (18.6 + or - 13.3 microg/L vs 18.4 + or - 8.9 microg/L, P = 0.95), cortisol level (11.1 + or - 4.8 microg/dL vs 12.6 + or - 4.3 microg/dL, P = 0.15) and PTH level (42.7 + or - 38 microg/dL vs 34.8 + or - 10.9 microg/dL, P = 0.27) were not significantly different.


CONCLUSIONS
Hepatic osteodystrophy is an important complication encountered in patients with liver cirrhosis and all patients should be monitored for hepatic osteodystrophy.
Goral
Vedat
V
Department of Gastroenterology, Dicle University School of Medicine, 21280 Diyarbakir, Turkey. vegoral@hotmail.com
Simsek
Mehmet
M
Mete
Nuriye
N
D015502:Absorptiometry, Photon / Q000379:methods; D000328:Adult; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000175:diagnosis* / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007375:Interleukin-1 / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000473:pathology; D008107:Liver Diseases / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D007375:Interleukin-1; D010281:Parathyroid Hormone; D014409:Tumor Necrosis Factor-alpha; D007334:Insulin-Like Growth Factor I